Vanda Pharmaceuticals Inc. (VNDA) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 57.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,338 shares of the biopharmaceutical company’s stock after selling 80,835 shares during the quarter. JPMorgan Chase & Co.’s holdings in Vanda Pharmaceuticals were worth $1,071,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the business. California Public Employees Retirement System raised its holdings in Vanda Pharmaceuticals by 3.8% during the second quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock worth $971,000 after purchasing an additional 2,200 shares in the last quarter. Legal & General Group Plc raised its holdings in Vanda Pharmaceuticals by 37.4% during the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Vanda Pharmaceuticals by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 199,578 shares of the biopharmaceutical company’s stock worth $3,573,000 after purchasing an additional 3,305 shares in the last quarter. Voya Investment Management LLC raised its holdings in Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Vanda Pharmaceuticals by 1.6% during the second quarter. PNC Financial Services Group Inc. now owns 318,788 shares of the biopharmaceutical company’s stock worth $5,196,000 after purchasing an additional 4,986 shares in the last quarter. 88.43% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at $14.50 on Friday. The company has a market cap of $651.45, a price-to-earnings ratio of -45.31 and a beta of 1.29. Vanda Pharmaceuticals Inc. has a 1-year low of $11.90 and a 1-year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.01) EPS. research analysts predict that Vanda Pharmaceuticals Inc. will post -0.44 EPS for the current year.

A number of research firms have weighed in on VNDA. Oppenheimer reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 8th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a report on Wednesday, October 18th. ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, Piper Jaffray Companies set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 19th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.50.

In other Vanda Pharmaceuticals news, SVP Gunther Birznieks sold 8,568 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total value of $130,747.68. Following the transaction, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the completion of the transaction, the insider now directly owns 1,031,848 shares in the company, valued at $15,787,274.40. The disclosure for this sale can be found here. Insiders sold a total of 209,483 shares of company stock worth $3,205,205 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thestockobserver.com/2018/01/13/vanda-pharmaceuticals-inc-vnda-shares-sold-by-jpmorgan-chase-co.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply